Research programme: antimicrobial immunoconjugate cancer therapeutics - Cidara Therapeutics
Latest Information Update: 16 Mar 2022
At a glance
- Originator Cidara Therapeutics
- Class Antibacterials; Antineoplastics; Drug conjugates; Immunoconjugates; Immunoglobulin Fc fragments
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 31 Jan 2022 Research programme: antimicrobial immunoconjugate cancer therapeutics - Cidara Therapeutics is available for licensing as of 31 Jan 2022. https://www.cidara.com/
- 31 Jan 2022 Cidara Therapeutics has eight families of patent applications related to the CloudbreakTM immunotherapy platform
- 31 Jan 2022 Early research in Solid tumours in USA (Parenteral) (Cidara Therapeutics pipeline, January 2022)